Gefitinib is a so-called targeted cancer therapy. It inhibits the growth of rapidly dividing cells, especially in tumours that carry a specific change (mutation) in the EGFR gene. This mutation can be detected with a laboratory test.
Other rapidly renewing tissues, such as mucous membranes and skin, also rely on EGFR signals for normal cell growth. As a result, these tissues may also be affected, which can lead to side effects.
Gefitinib is used to treat certain types of non-small cell lung cancer. The medicine is particularly suitable when the tumour contains an EGFR mutation.
Gefitinib and the benefit of DNA analysis
The rate at which gefitinib is processed within your body varies from one individual to another. This means that the efficacy and side effects of gefitinib can be predicted to some extent on the basis of your genes. Preventive DNA analysis can therefore be an important tool in optimising your medication.
Risperidone and the enzyme CYP2D6
Gefitinib is processed to a large extent by the enzyme CYP2D6. The activity of this enzyme can vary considerably depending on your genetic predisposition, which means the efficacy of gefitinib can also differ from person to person.
Information about your genetic predisposition may therefore provide grounds for extra vigilance in relation to a treatment with gefitinib.
Read more about CYP2D6 enzyme »
Also known as
Iressa